Almirall

Almirall, S.A. is a biopharmaceutical company focused on skin health, operating in Spain, Europe, the Middle East, the United States, Asia, and Africa. It offers products for skin diseases such as psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for other therapeutic areas including alimentary tract and metabolism, anti-infectives, cardiovascular, dermatological, genitourinary and sex hormones, immunostimulants, musculo-skeletal, nervous system, respiratory, and systemic hormonal preparations. The company is developing tirbanibulin for actinic keratosis and tildrakizumab for psoriatic arthritis (registration phase), lebrikizumab for pediatric atopic dermatitis (phase 2), and several other candidates in phase 2, phase 1, and preclinical stages. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. Formerly known as Laboratorios Almirall, S.A., it changed its name to Almirall, S.A. in May 2009 and was founded in 1943, headquartered in Barcelona, Spain.